## **POLICY AND PROCEDURES**

## OFFICE OF THE CENTER DIRECTOR

# **Commitment of CDER Central Funds to Support Intercenter Science Projects**

## **Table of Contents**

PURPOSE	1
BACKGROUND	
POLICY	
RESPONSIBILITIES	
PROCEDURES	
SUMMARY OF CHANGES	
EFFECTIVE DATE	
CHANGE CONTROL TABLE	
ATTACHMENT 1: Proposal Form	
ATTACHMENT 2: CDER Central funds Workflow	

## **PURPOSE**

This MAPP establishes the policies and procedures for submission, review and approval of science project proposals from collaborating FDA Organizations outside of CDER<sup>1</sup> that require funding by CDER Central Funds<sup>2</sup>. For the purposes of this MAPP, these projects are hereafter referred to as "Intercenter Projects." This MaPP also describes responsibilities of CDER staff in the review, prioritization, approval, and tracking, of Intercenter Projects, and sets expectations for FDA Organizations requesting funding by CDER Central Funds to support Intercenter Projects.

## **BACKGROUND**

CDER scientists engage in a number of scientific collaborations with other FDA Organizations. These collaborations support CDER's regulatory science objectives and enhance the professional development of CDER staff. Where collaborations proposed either by CDER staff or by the collaborating FDA Organization will require transfer via requisition or other mechanism of CDER central funds to the collaborating Center, there is a need for clear policy and procedures for reviewing, prioritizing, approving, and

Originating Office: Office of Center Director

Effective Date: <del>12/14/15</del>, 3/07/16 Page 1 of 12

<sup>&</sup>lt;sup>1</sup> This includes FDA Centers and organizations within the Office of the Commissioner, including ORA <sup>2</sup> This MAPP applies only to Intercenter Projects that involve funds from the CDER Central Fund. This MAPP does NOT apply to Intercenter Projects that involve funding from a CDER Office's budget.

tracking Intercenter Project proposals to ensure that they support CDER's science and research priorities.

## **POLICY**

- This MAPP only applies to Intercenter Projects which require funding from CDER's Central account to support the work of a collaborating FDA Organization. It does NOT apply to collaborative projects with FDA Organization directly funded from an approved CDER Office budget
- Each Intercenter Project requiring funding from CDER Central account to a collaborating FDA Organization must be:
  - o Described in an Intercenter Project proposal form (Attachment 1)
  - Submitted to the Division of Budget Execution and Resources (DBERM) in CDER's Office of Management for verification of available funds to support the project prior to review
  - Reviewed by appropriate CDER subject matter experts for scientific quality,
     CDER mission relevance, and potential impact
  - Recommended for funding by the appropriate CDER Office Director or designee<sup>3</sup>
  - o Assigned a CDER Project Lead if one has not been identified
  - o Reviewed by the CDER Financial Council, and
  - o Approved by the CDER Center Director
  - o Tracked by the Office of Translational Sciences
- All requests for Central Funds during a given fiscal year must be received by DBERM by March 1
- All requests received by DBERM by March 1 will be reviewed and prioritized in a single yearly review process managed by OTS
- Subsequent review of prioritized proposals by the Financial Council and CDER
  Center Director will be completed by April 1 and Collaborating FDA Organizations
  will be notified of funding decisions by April 15
- Funds needed to address immediate and urgent threats to public health and safety may be exempted from the process described in this MAPP

## RESPONSIBILITIES

Collaborating FDA Organization

- Approves development of Intercenter Project proposals by FDA Organization staff
- Identifies a single point of contact within their FDA Organization to manage communications and submissions related to all project proposals requiring CDER Central Funds

Originating Office: Office of Center Director

Effective Date: <del>12/14/15</del>, 3/07/16 Page 2 of 12

<sup>&</sup>lt;sup>3</sup> The CDER Office Director may delegate this decision, but must document concurrence

- Seeks relevant CDER concurrence to ensure Intercenter Project proposal addresses a specific CDER need
- Drafts the project proposal in consultation with the CDER Project Lead (if one has been identified) and completes the Intercenter Project proposal form (Attachment 1)
- Provides oversight for each project and commits to obligating all CDER funds by the end of each fiscal year
- Provides to the CDER Project Lead and OTS IPC an annual progress report and/or a final report for each project supported by CDER Central Funds by Oct 31 of each year

Director, Division of Budget Execution and Resources, CDER Office of Management or designee (DBERM)

- Receives the Intercenter Project proposals from FDA Organizations and confirms the availability of funds in the CDER Central Account
- Sends all proposals received by CDER by March 1 for which funds may be available to OTS IPC for scientific review and prioritization
- Manages the CDER Financial Council and CDER Center Director review of prioritized funding requests/justifications prepared by OTS
- Sends the list of approved Intercenter Project proposals and funding amounts to the collaborating FDA Organization point of contact and to the OTS IPC

# OTS Intercenter Project Coordinator (OTS IPC)

- Is appointed by the Office of Translational Sciences
- Manages the scientific review of FDA Organizational proposals forwarded by DBERM
- Collates the scientific review comments and provides prioritized project proposal list to DBERM
- Tracks all funded projects and provides annual summary report on new and ongoing projects to DBERM and CDER leadership

# CDER Project Lead (CDER PL):

- For CDER initiated project proposals, after receiving Office Director concurrence, determines the interest of an appropriate collaborating FDA Organization in developing an Intercenter Project proposal
- With supervisory and Office Director concurrence, provides the collaborating FDA Organization with guidance on the scope, goals, and terms of an Intercenter Project proposal to ensure optimization of CDER's investment

Originating Office: Office of Center Director

Effective Date: <del>12/14/15</del>, 3/07/16 Page 3 of 12

- Monitors progress of the Intercenter Project, receives progress or final reports prepared by the collaborating FDA Organization, and forwards to the CDER Office Director and to the OTS IPC
- Updates the CDER science projects database with the approved Intercenter Projects and with annual updates.

# CDER Office Director (OD) or designee

- Determines if proposed research collaborations will support the scientific objectives of the CDER Office
- Provides written review, determines priority, and recommends whether each Intercenter Project Proposal should receive CDER funding
- Identifies and/or approves the CDER PL for Intercenter Projects submitted by FDA Organization
- Reviews annual project updates

## CDER Financial Council (FC)

 Reviews the Intercenter Project proposals and requests for funds and then makes recommendations to the CDER Center Director

## CDER Center Director

 Reviews the Financial Council's recommendations and provides final approval or denial of each funding request associated with an Intercenter Project

## **PROCEDURES**

The Intercenter Project proposal request process can be initiated by a CDER Office or by another FDA Organization. In each case, all Intercenter Project proposal forms from a given FDA Organization (Attachment 1) must be completed and transmitted to CDER/DBERM by a single point of contact representing the collaborating FDA Organization. A flow diagram for this process is captured in Attachment 2.

## **Proposal Development**

- Proposal Development CDER-Initiated Intercenter Projects
  - 1. The CDER PL, with supervisory and Office concurrence, may engage directly with a colleague in a collaborating FDA Organization to determine their

Originating Office: Office of Center Director

Effective Date: <del>12/14/15</del>, 3/07/16 Page 4 of 12

- interest and ensure concurrence from their management in developing the project proposal
- 2. If the CDER PL is unable to identify an appropriate collaborator in an FDA Organization, they should request assistance from the OTS IPC
- 3. The FDA Organization collaborator, in consultation with the CDER PL, completes Intercenter Project proposal form (Attachment 1) for initial review by the collaborating FDA Organization
- 4. The collaborating FDA Organization submits the Intercenter Project form to CDER/DBERM by March 1 following procedures outlined under *Submission*, *Review and Approval of Intercenter Project Proposals*, below

# • Proposal Development - FDA Center-Initiated Intercenter Projects

- 1. The FDA Organization drafts the project proposal in consultation with the CDER PL (if one has been identified) and completes the Intercenter Project proposal form (Attachment 1)
- 2. If the request is to extend an ongoing project, a detailed progress report must be attached to the Intercenter Project proposal form
- 3. The collaborating FDA Organization, after following its internal review and clearance procedures, submits the Intercenter Project proposal to CDER/DBERM by March 1 following procedures outlined below

## Submission, Review and Approval of Intercenter Project Proposals

- 1. The single point of contact from the collaborating FDA Organizations may submit Intercenter Project proposal forms along with any progress reports to DBERM in Office of Management, CDER on before March 1
- 2. DBERM determines availability of CDER Central Funds
- 3. DBERM sends the Intercenter Project proposal forms and statement of available funds to the OTS IPC, who compiles and catalogues all proposals received prior to March 1 and identifies the appropriate CDER Office to review the proposal
- 4. On March 15, OTS IPC initiates the annual review process by sending the Intercenter Project proposal forms to the appropriate CDER Offices for review and prioritization
- 5. If CDER OD endorses the proposal, he or she identifies a CDER PL if a CDER PL has not already been identified by the FDA Organization

Originating Office: Office of Center Director

Effective Date: <del>12/14/15</del>, 3/07/16 Page 5 of 12

- 6. CDER PL negotiates with the collaborating FDA Organization any modifications needed to the scope, goals and terms of the Intercenter Project proposal to ensure optimization of CDER's investment
- 7. CDER OD or designee provides review, rating and prioritization of the final Intercenter Project proposal to the OTS IPC
- 8. OTS IPC collates Office Director (or designee) reviews, prioritization and recommendations for all Intercenter Project proposals and sends this information to DBERM
- 9. DBERM submits the justification, including feedback and funding requests for all Intercenter Projects to the Financial Council
- 10. The FC reviews the Intercenter Project proposal and justification and then makes a recommendation to the CDER Center Director
- 11. CDER Center Director reviews the Financial Council's recommendations and provides final approval or denial of the funding request associated with the Intercenter Project
- 12. DBERM sends a list of approved Intercenter Projects to the FDA Organization IPC and CDER IPC
- 13. CDER IPC maintains a record of approved Intercenter Projects
- 14. CDER IPC informs the OD and CDER PL of approved Intercenter Projects
- 15. The CDER PL receives annual updates on approved Intercenter projects from the collaborating FDA Organization and provides copies to the OD and CDER IPC

#### **SUMMARY OF CHANGES**

1. Rev. 1

#### **EFFECTIVE DATE**

This MAPP is effective upon date of publication.

Originating Office: Office of Center Director

Effective Date: <del>12/14/15</del>, 3/07/16 Page 6 of 12

# MANUAL OF POLICIES AND PROCEDURES

# CENTER FOR DRUG EVALUATION AND RESEARCH

**MAPP 4200.5** 

# **CHANGE CONTROL TABLE**

Effective	Revision	Revisions
Date	Number	
	Initial	N/A

Originating Office: Office of Center Director Effective Date: 12/14/15, 3/07/16 Page 7 of 12

# **ATTACHMENT 1: Proposal Form**

CDER IPC Use Only		t of CDER Cent r Science Proje	ral Fund		
	Please refer to the MA	PP 4200.5 when complet	ing this form		
Principal Investige	ator				
Last Name		First Name	•		
FDA Center	<b>-</b>	Division/O	office		
Project Co-Lead's a	and Other Study Personnel	should be added to the i	Personnel sec	tion on page 3	
Project Title					
		Topic Areas			
OA Strategic Plan for Re	gulatory Science C	DER Regulated Products	CE	DER Science Needs	
	¥		-		•
http://	Click on inside.fda.gov:9003/downloads/	link below for list of topic area ProgramsInitiatives/Drugs/Sci		JCM414050.pdf	
	supported by CDER?				
	Over ove If	YES - Title			_
To attach your report  1. Click on paper clip 2. Browse for and se	on results of an ongoing project please on the lower left.	t, you MUST attach a summ	ary of progress		
	ave you applied for other FDA in provide the following information		○ NO nu, please type ir	1	
Funding Program	m	Project Title		Current Funding Amount	
Are you attaching  Yes No	any supplemental information?	(i.e., budget justification, prog	ress report, grap	ohs, methods)	

Originating Office: Office of Center Director Effective Date: 12/14/15, 3/07/16

Effective Date: <del>12/14/15</del>, 3/07/16 Page 8 of 12

	Goal or Impact
	Limit to 1-2 paragraphs, suggested length no more than 500 words. (note: box will expand to fit text)
	December / Decident Plans
	Research / Project Plan  Background
	8/C3000000 <del>27 C</del> 3000000000
	Limit to 1000 words (note: box will expand to fit text)
	Methods
ovide description of anology to be used	of methods or specific project plan; for example, include the specific statistical analyses, experimental design, or d.
ease also provide s	scientific contribution and role of each participant. Sient detail for evaluation by an expert in the field.
	te: box will expand to fit text)
	_Specific Goals/Milestones
eludo timolinos o	wasted deliverables and assemblishments (for multi-very projects the deliverables for each year
	xpected deliverables, and accomplishments (For multi-year projects, the deliverables for each year ontinuing projects must make clear for which year funding is being requested).  oject
	box will expand to fit text)

Originating Office: Office of Center Director Effective Date: 12/14/15, 3/07/16

Effective Date: <del>12/14/15</del>, 3/07/16 Page 9 of 12


	Name	Office/Division	Role	Employee Type	Effort (hr/wk)	Immediate Supervisor
dd Row						
		If an unneeded row is added i	nadvertently please lea	ve blank.		
	FD	A Center Collabo	<b>orators</b> (list a	II, if know	n)	
	Name	Center (e.g CBER,NCTR) Center (		er Office	Center Division/Lab	
dd Row						
e budget sh awarded.		requesting for the fiscal yea	9 12 5 5 10 (200 ) THE FIFTH OF BUILDING THE TOTAL CHILDREN	all funds mus		
	Budget Category	Item Description			Justification Co	
dd Row	•					
		If an unneeded row is added i	nadvertently please lea	ve blank.		
					Budg	get Total

Originating Office: Office of Center Director Effective Date: 12/14/15, 3/07/16 Page 10 of 12

Approvals/ Ack	nowledgements
FDA Center PI Signature	Date
CDER Project Lead Signature	Date
Center IPC Signature	Date
DBERM/Designee Signature	Date
CDER IPC Signature	Date
CDER Office Director Signature	Date
CDER FC Chair Signature	Date
CDER Center Director Signature	Date
e60dsfa-2459-484a-	3637-6637d0f905ce

Originating Office: Office of Center Director Effective Date: <del>12/14/15</del>, 3/07/16

## **ATTACHMENT 2: CDER Central funds Workflow**



Originating Office: Office of Center Director

Effective Date: <del>12/14/15</del>, 3/07/16 Page 12 of 12